Lead Product(s): rhGAD65
Therapeutic Area: Endocrinology
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
The patents protect the administration method of Diamyd® that is now being evaluated in the Phase IIb trial DIAGNODE-2, which previously showed positive results in the Phase I/II trial DIAGNODE-1.